Sign Out
Rebif is available in 2 strengths: 22 and 44 mcg.
Recommended Dose: 44 mcg given 3 times weekly by SC injection. Rebif 22 mcg is also given 3 times weekly by SC injection for patients who cannot tolerate the higher dose in view of the treating specialist.
Treatment should be initiated under the supervision of a physician experienced in the treatment of the disease.
When starting treatment with Rebif, it is recommended that the dose be gradually increased in order to allow development of tachyphylaxis; thus, reducing the risk of adverse reactions. It is recommended that 20% of the total dose be administered during the first 2 weeks of therapy; 50% of the total dose be administered in the 3rd and 4th weeks; and the full dose be administered from the 5th week and onwards.
Children and Adolescents: No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, limited published data suggest that the safety profile in adolescents from 12-16 years receiving Rebif 22 mcg SC 3 times weekly is similar to that seen in adults. There is very limited information on the use of Rebif in children <12 years; therefore, Rebif should not be used in this population.
Prior to injection and for an additional 24 hrs after each injection, an antipyretic-analgesic is advised to decrease flu-like symptoms associated with Rebif administration.
At the present time, it is not known for how long patients should be treated. Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment. It is recommended that patients should be evaluated at least every 2nd year in the 4-year period after initiation of treatment with Rebif, and a decision for long-term treatment should then be made on an individual basis by the treating physician.
